Orphan Drug

(Image: iStock/Hankimage9)

Ergomed to acquire orphan drug CRO for €5.7m

By Melissa Fassbender

Ergomed is bolstering its orphan drug development services with its acquisition of PSR Group BV in a deal worth up to €5.7m ($6.69m) – which will position the company to be a “global player” in the area, says CEO.

Orphan drug CROs look to capitalize on influx of biotech cash

Orphan drug CROs look to capitalize on influx of biotech cash

By Zachary Brennan

As small biotech companies continue to cash in on new investments, IPOs and increasing approval rates of orphan and rare disease drugs, CROs are cashing in too and helping the companies navigate the regulatory and clinical landscape.

Spotlight

Follow us

Featured Events

View more

Products

View more

Webinars

Featured Suppliers

All suppliers